Teva Pharmaceuticals is trading 10.5% up today at $10,590 after releasing better-than-expected Q2 2026 results and hosting its earnings conference call.
- The company reported Q2 2026 revenue of $4.14 billion, surpassing analyst estimates.
- Management highlighted significant progress in its Pivot to Growth strategy, which investors appear to be rewarding despite broader market caution.
- The positive price action follows detailed commentary provided during the company's quarterly earnings presentation.